SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 08:30:44 04/06/2024 pm IST | ||
| 27.77 EUR | +0.95% |
|
| Current month | -1.08% | ||
| 1 month | +4.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 27.77 | +0.95% |
| 03/24/03 | 27.51 | -1.08% |
| 31/24/31 | 27.81 | -0.36% |
| 30/24/30 | 27.91 | -0.82% |
| 29/24/29 | 28.14 | +0.50% |
Delayed Quote Deutsche Boerse AG
Last update June 04, 2024 at 08:30 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VX25JS |
| ISIN | DE000VX25JS3 |
| Date issued | 05/11/2021 |
| Strike | 4,022 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 16.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.46 € |
|---|---|
| Lowest since issue | 9.64 € |
| Spread | 0.48 € |
| Spread % | 1.70% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,954
DKK
Average target price
2,464
DKK
Spread / Average Target
+26.13%
- Stock Market
- Certificates
- Certificat
